For instance, a numerically higher progression-free survival (PFS) was observed in the phase III registrational study of relatlimab in combination with nivolumab for those tumor samples with LAG-3 overexpression assessed by immunohistochemistry [39]. This evidence concerns the gene LAG3 and neoplasm.